How to Trip Rapid Review

Step 1: Select articles relevant to your search (remember the system is only optimised for single intervention studies)

Step 2: press

Step 3: review the result, and maybe amend the or if you know better! If we're unsure of the overall sentiment of the trial we will display the conclusion under the article title. We then require you to tell us what the correct sentiment is.

8,374 results for

Alopecia

by
...
Latest & greatest
Alerts

Export results

Use check boxes to select individual results below

SmartSearch available

Trip's SmartSearch engine has discovered connected searches & results. Click to show

1. Alopecia areata

Alopecia areata Evidence Maps - Trip Database or use your Google+ account Liberating the literature ALL of these words: Title only Anywhere in the document ANY of these words: Title only Anywhere in the document This EXACT phrase: Title only Anywhere in the document EXCLUDING words: Title only Anywhere in the document Timeframe: to: Combine searches by placing the search numbers in the top search box and pressing the search button. An example search might look like (#1 or #2) and (#3 or #4

2018 Trip Evidence Maps

2. Alopecia

Alopecia Evidence Maps - Trip Database or use your Google+ account Turning Research Into Practice ALL of these words: Title only Anywhere in the document ANY of these words: Title only Anywhere in the document This EXACT phrase: Title only Anywhere in the document EXCLUDING words: Title only Anywhere in the document Timeframe: to: Combine searches by placing the search numbers in the top search box and pressing the search button. An example search might look like (#1 or #2) and (#3 or #4

2018 Trip Evidence Maps

5. Androgenic alopecia

Androgenic alopecia Androgenic alopecia - Symptoms, diagnosis and treatment | BMJ Best Practice You'll need a subscription to access all of BMJ Best Practice Search  Androgenic alopecia Last reviewed: February 2019 Last updated: March 2018 Summary Also known as pattern baldness, androgenic alopecia is a genetically determined, patterned, progressive loss of hair from the scalp and occurs in both men and women. Both androgens and genetics play a role in its pathogenesis. The term androgenic (...) alopecia is best used only when referring to male-pattern hair loss, as most females likely do not share the androgenic pathway. A more appropriate term for women is female-pattern hair loss. The term pattern hair loss will be used when referring to hair loss affecting both sexes. Men present with hair thinning in the temporal areas that advances to the crown (vertex) area as the alopecia progresses. Women usually have more diffuse thinning on the crown area, and less commonly present with a male-type

2018 BMJ Best Practice

6. Alopecia

Alopecia Top results for alopecia - Trip Database or use your Google+ account Find evidence fast ALL of these words: Title only Anywhere in the document ANY of these words: Title only Anywhere in the document This EXACT phrase: Title only Anywhere in the document EXCLUDING words: Title only Anywhere in the document Timeframe: to: Combine searches by placing the search numbers in the top search box and pressing the search button. An example search might look like (#1 or #2) and (#3 or #4 (...) ) Loading history... Population: Intervention: Comparison: Outcome: Population: Intervention: Latest & greatest articles for alopecia The Trip Database is a leading resource to help health professionals find trustworthy answers to their clinical questions. Users can access the latest research evidence and guidance to answer their clinical questions. We have a large collection of systematic reviews, clinical guidelines, regulatory guidance, clinical trials and many other forms of evidence. If you wanted

2018 Trip Latest and Greatest

7. ATI-501 Oral Suspension Compared to Placebo in Subjects With Alopecia Areata, Alopecia Universalis or Alopecia Totalis

ATI-501 Oral Suspension Compared to Placebo in Subjects With Alopecia Areata, Alopecia Universalis or Alopecia Totalis ATI-501 Oral Suspension Compared to Placebo in Subjects With Alopecia Areata, Alopecia Universalis or Alopecia Totalis - Full Text View - ClinicalTrials.gov Hide glossary Glossary Study record managers: refer to the if submitting registration or results information. Search for terms x × Study Record Detail Saved Studies Save this study Warning You have reached the maximum (...) number of saved studies (100). Please remove one or more studies before adding more. ATI-501 Oral Suspension Compared to Placebo in Subjects With Alopecia Areata, Alopecia Universalis or Alopecia Totalis The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our for details. ClinicalTrials.gov Identifier: NCT03594227 Recruitment Status : Active

2018 Clinical Trials

8. Risk of sun-induced skin cancers in patients with alopecia areata, alopecia totalis and alopecia universalis. (PubMed)

Risk of sun-induced skin cancers in patients with alopecia areata, alopecia totalis and alopecia universalis. 29679494 2018 10 27 1468-3083 32 11 2018 Nov Journal of the European Academy of Dermatology and Venereology : JEADV J Eur Acad Dermatol Venereol Risk of sun-induced skin cancers in patients with alopecia areata, alopecia totalis and alopecia universalis. e409-e411 10.1111/jdv.15002 Conic R R Z RRZ Department of Dermatology, Cleveland Clinic Foundation, Cleveland, OH, USA. Department

2018 Journal of the European Academy of Dermatology and Venereology

9. ATI-502 Topical Solution for the Treatment of Alopecia Areata (AA), Alopecia Universalis (AU) and Alopecia Totalis (AT)

ATI-502 Topical Solution for the Treatment of Alopecia Areata (AA), Alopecia Universalis (AU) and Alopecia Totalis (AT) ATI-502 Topical Solution for the Treatment of Alopecia Areata (AA), Alopecia Universalis (AU) and Alopecia Totalis (AT) - Full Text View - ClinicalTrials.gov Hide glossary Glossary Study record managers: refer to the if submitting registration or results information. Search for terms x × Study Record Detail Saved Studies Save this study Warning You have reached the maximum (...) number of saved studies (100). Please remove one or more studies before adding more. ATI-502 Topical Solution for the Treatment of Alopecia Areata (AA), Alopecia Universalis (AU) and Alopecia Totalis (AT) The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. of clinical studies and talk to your health care provider before participating. Read our for details

2018 Clinical Trials

10. Alopecia areata

Alopecia areata Alopecia areata - Symptoms, diagnosis and treatment | BMJ Best Practice You'll need a subscription to access all of BMJ Best Practice Search  Alopecia areata Last reviewed: February 2019 Last updated: November 2017 Summary Autoimmune disease that targets the hair follicle. Characterised by sudden onset of patchy hair loss. Diagnosis is clinical. Characteristic physical findings are exclamation mark hairs (short, broken hairs) and a positive pull test. A scalp biopsy shows (...) perifollicular inflammation. Topical or intralesional corticosteroids are appropriate for patients with limited hair loss. Skin atrophy can be a temporary side effect. Definition Alopecia areata (AA) is an autoimmune disease that affects almost 2% of the population in the US. Safavi KH, Muller SA, Suman VJ, et al. Incidence of alopecia areata in Olmsted County, Minnesota, 1975 through 1989. Mayo Clin Proc. 1995;70:628-633. http://www.ncbi.nlm.nih.gov/pubmed/7791384?tool=bestpractice.com Inflammatory cells

2017 BMJ Best Practice

11. Is there a pathogenetic link between frontal fibrosing alopecia, androgenetic alopecia, and fibrosing alopecia in a pattern distribution? (PubMed)

Is there a pathogenetic link between frontal fibrosing alopecia, androgenetic alopecia, and fibrosing alopecia in a pattern distribution? 29224248 2018 06 07 1468-3083 32 6 2018 Jun Journal of the European Academy of Dermatology and Venereology : JEADV J Eur Acad Dermatol Venereol Is there a pathogenetic link between frontal fibrosing alopecia, androgenetic alopecia and fibrosing alopecia in a pattern distribution? e218-e220 10.1111/jdv.14748 Katoulis A C AC 2nd Department of Dermatology

2017 Journal of the European Academy of Dermatology and Venereology

12. Naltrexone for Alopecia: Clinical Effectiveness

Naltrexone for Alopecia: Clinical Effectiveness Naltrexone for Alopecia: Clinical Effectiveness | CADTH.ca Find the information you need Naltrexone for Alopecia: Clinical Effectiveness Naltrexone for Alopecia: Clinical Effectiveness Published on: August 8, 2016 Project Number: RA0859-000 Product Line: Research Type: Drug Report Type: Reference List Result type: Report Question What is the clinical effectiveness of naltrexone for the treatment of alopecia? Key Message No literature (...) was identified regarding the clinical effectiveness of naltrexone for the treatment of alopecia. Tags alopecia, hair, naltrexone, other miscellaneous topics, hair loss, hairloss Files Rapid Response Reference List Published : August 8, 2016 Follow us: © 2019 Canadian Agency for Drugs and Technologies in Health Get our newsletter:

2016 Canadian Agency for Drugs and Technologies in Health - Rapid Review

13. Multi-Concentration Level Patch Test Guided Diphenyl Cyclopropenone (DPCP) Treatment in Alopecia Totalis or Alopecia Universalis. (PubMed)

Multi-Concentration Level Patch Test Guided Diphenyl Cyclopropenone (DPCP) Treatment in Alopecia Totalis or Alopecia Universalis. Diphenylcyclopropenone (DPCP) has proved to be effective in alopecia areata. The present study aimed to shorten the treatment duration of DPCP for achieving optimal outcomes.To evaluate the efficacy of multi-concentration level patch test guided DPCP treatment against conventional protocol by measuring percentage of hair regrowth and duration of treatment.The scalp (...) was divided into experimental and control sites. Conventional DPCP sensitization and experimental patch test with multi-level of DPCP concentration were applied in 20 alopecia totalis or universalis patients. The percentages of hair regrowth were evaluated.Five patients achieved complete response within 34 weeks. Mean duration of the experimental sites was shorter although there was no significant difference. Reported complications of both groups were vesicle formation, generalized eczema

2018 Journal of the Medical Association of Thailand = Chotmaihet thangphaet

14. Cicatricial Alopecia Research Foundation Meeting, May 2016: Progress Towards the Diagnosis, Treatment, and Cure of Primary Cicatricial Alopecias. (PubMed)

Cicatricial Alopecia Research Foundation Meeting, May 2016: Progress Towards the Diagnosis, Treatment, and Cure of Primary Cicatricial Alopecias. Primary cicatricial alopecias (PCAs) are a group of skin diseases in which there is progressive and permanent destruction of hair follicles followed by replacement with fibrous tissue. Unfortunately, by the time patients seek clinical evaluation of their hair loss, the skin is already inflamed and/or scarred, so there is little hope for a return (...) to their normal hair growth pattern. Clinical and basic science investigations are now focusing on three forms of human PCA: lichen planopilaris (LPP), frontal fibrosing alopecia (FFA) and central centrifugal cicatricial alopecia (CCCA). Transcriptome, lipidome and other new technologies are providing new insight into the pathogenesis of some of these diseases that are being validated and further investigated using spontaneous and genetically engineered mouse models.© 2018 John Wiley & Sons A/S. Published

2018 Experimental Dermatology

15. CME Part 2: Hair disorders in cancer survivors Persistent chemotherapy-induced alopecia, persistent radiotherapy-induced alopecia, and hair growth disorders related to endocrine therapy or cancer surgery. (PubMed)

CME Part 2: Hair disorders in cancer survivors Persistent chemotherapy-induced alopecia, persistent radiotherapy-induced alopecia, and hair growth disorders related to endocrine therapy or cancer surgery. With increasing survival rates across all cancers, survivors represent a growing population that is frequently affected by persistent or permanent hair growth disorders as a result of systemic therapies, radiotherapy, surgical procedures, and therapeutic transplants. These hair disorders (...) include persistent chemotherapy-induced alopecia, persistent radiotherapy-induced alopecia, endocrine therapy-induced alopecia and hirsutism, post-surgery alopecia and localized hypertrichosis, alopecia attributed to therapeutic transplants, and to novel anticancer therapies. The information contained in this continuing medical education article should facilitate a better understanding on hair disorders in cancer survivors, so that adequate support and therapies may be provided to cancer

2018 Journal of American Academy of Dermatology

16. Quality of Life with Alopecia Areata versus Androgenetic Alopecia Assessed Using Hair Specific Skindex-29 (PubMed)

Quality of Life with Alopecia Areata versus Androgenetic Alopecia Assessed Using Hair Specific Skindex-29 29853767 2018 11 14 1013-9087 30 3 2018 Jun Annals of dermatology Ann Dermatol Quality of Life with Alopecia Areata versus Androgenetic Alopecia Assessed Using Hair Specific Skindex-29. 388-391 10.5021/ad.2018.30.3.388 Jun Myungsoo M Department of Dermatology and Institute of Hair and Cosmetic Medicine, Yonsei University Wonju College of Medicine, Wonju, Korea. Keum Dong In DI Department

Full Text available with Trip Pro

2018 Annals of dermatology

17. HrQoL in hair loss affected patients with Alopecia Areata, Androgenetic Alopecia and Telogen Effluvium: The role of personality traits and psychosocial anxiety. (PubMed)

HrQoL in hair loss affected patients with Alopecia Areata, Androgenetic Alopecia and Telogen Effluvium: The role of personality traits and psychosocial anxiety. Illness impact on HrQoL has been widely studied in hair loss-affected patients, yet no study has addressed whether individual differences modulate HrQoL in patients with alopecia areata (AA), androgenetic alopecia (AGA) and telogen effluvium (TE).To identify the personality dimensions most predictive of the impact of disease on HrQoL.A (...) single-site cross-sectional study was carried out in the Dermatology Unit of Sant'Orsola-Malpighi Hospital, Bologna between September 2016 and September 2017. The study included 143 patients (105 females, ages 18-60 years) diagnosed with AA (n = 27), AGA (n = 80) and TE (n = 36). Illness severity, alopecia type, age, gender, education and civil status were documented. Health-related quality of life (HrQoL), personality traits, trait anxiety, emotional intelligence, social anxiety and social phobia

2018 Journal of the European Academy of Dermatology and Venereology

18. Utility of Horizontal Sections of Scalp Biopsies in Differentiating between Androgenetic Alopecia and Alopecia Areata. (PubMed)

Utility of Horizontal Sections of Scalp Biopsies in Differentiating between Androgenetic Alopecia and Alopecia Areata. Androgenetic alopecia (AGA) and alopecia areata (AA) are common causes of alopecia which can sometimes be difficult to differentiate clinically. Horizontal sections of scalp biopsies are used to study non-cicatricial alopecias due to the ability to perform both quantitative and morphometric analysis of hair follicles on them.It was a prospective, cross-sectional study conducted (...) to assess the utility of horizontal sections to differentiate between the alopecias. Fifty-two cases were included: 20 cases of male AGA, 11 of female AGA and 21 cases of AA. After clinical examination and dermoscopy, a skin biopsy was taken and subjected to transverse sectioning. Histopathological assessment was done by two dermatopathologists blinded to clinical details.Among the quantitative parameters, terminal:vellus hair ratio (3.08 in AGA and 1.83 in AA, p = 0.0091) and anagen:non-anagen hair

2018 Dermatology

19. The value of dermoscopy in diagnosing eyebrow loss in patients alopecia areata and frontal fibrosing alopecia. (PubMed)

The value of dermoscopy in diagnosing eyebrow loss in patients alopecia areata and frontal fibrosing alopecia. Alopecia areata and frontal fibrosing alopecia are common causes of eyebrow loss (madarosis).Assessment of trichoscopic markers of eyebrow loss in alopecia areata and frontal fibrosing alopecia.The analysis included 50 patients with scalp alopecia areata with madarosis, 50 patients with scalp frontal fibrosing alopecia with madarosis and 50 healthy controls. In every case, trichoscopy (...) of the eyebrow area was performed.Empty follicular and eccrine duct openings were observed in all patients and presented predominantly as yellow dots. Exclamation mark hairs were only detected in patients with alopecia areata (30%). Tapered hairs, broken hair, black dots and Pohl-Pinkus constrictions were observed in 14%, 36%, 26% and 4% of patients with alopecia areata, respectively, 4%, 16%, 2% and 0% of patients with frontal fibrosing alopecia, respectively, and they were not present in healthy controls

2018 Journal of the European Academy of Dermatology and Venereology

20. Do statins cause alopecia?

Do statins cause alopecia? Do statins cause alopecia? – SPS - Specialist Pharmacy Service – The first stop for professional medicines advice Do statins cause alopecia? · · Published 23rd March 2018, updated 23rd March 2018 · London Medicines Information Service Most UK licensed statins (hydroxymethylglutaryl coenzyme A reductase inhibitors) have been reported by manufacturers to cause hair loss as a side effect. This Medicines Q&A aims to review incidence of alopecia with UK licensed statins

2018 Specialist Pharmacy Services

To help you find the content you need quickly, you can filter your results via the categories on the right-hand side >>>>